1. EMA Assesment report Prevenar 13 pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) Procedure No: EMEA/H/C/001104/II/0028 www.ema.europa.eu
2. Khoie T, Tiernan R. deVore N FDA Briefing Document Prevnar 13™ (PCV13): Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) Applicant: Wyeth Pharmaceuticals Inc. Vaccines and Related Biological Products Advisory Committee November 16, 2011 www.fda.gov/./VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM279680.pdf
3. Haut Conseil de Santé publique. Avis relatif aux recommandations vaccinales spécifiques des personnes immunodéprimées ou aspléniques. 16 février 2012 www. HCSP
4. ACIP Provisional Recommendations for Use of 13-valent Pneumococcal Conjugate Vaccine in Adults with Immunocompromising Conditions. September 18, 2012 site CDC ACIP (www. cdc. gov/vaccines/acip/index. html).
5. Recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23);Nuorti;MMWR,2010